




Year-end report

20
25

Prostatype Genomics AB

A microscopic view of several cells, likely cancer cells, showing their nuclei and cytoplasm. The cells are rendered in a light blue, semi-transparent style against a dark blue background.

Summary

Second half of 2025

1 July – 31 December 2025

- Net sales amounted to 348 TSEK (84)
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -17,780 TSEK (-20,437)
- Cash flow from operating activities amounted to -6,722 TSEK (-21,499)
- Total cash flow for the period amounted to -3,846 TSEK (7,620)
- Earnings per share* amounted to -0.40 SEK (-5.00)

Full year 2025

1 January 2025 – 31 December 2025

- Net sales amounted to 594 TSEK (199)
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -36,751 TSEK (-38,874)
- Cash flow from operating activities amounted to -23,801 TSEK (-44,709)
- Total cash flow for the period amounted to -330 TSEK (6,686)
- Earnings per share* amounted to -1.32 SEK (-14.93)**

* Values for historic earnings per share have been recalculated to reflect the reversed share split 1000:1 which was carried out during the second half of 2024.

** The definition of earnings per share has been updated to be calculated on the average number of shares for the period instead of on the number of shares at the end of the period. All comparative figures have therefore been adjusted.



Significant events during the second half of 2025

During the second half of 2025, Prostatype Genomics continued to consolidate and further develop the company's commercial and scientific position, with a particular focus on the strategically important U.S. market and on strengthening the clinical evidence for the prognostic genomic test Prostatype®.

Commercial development in the U.S. market

During the period, the company took an important step in its commercialization in the United States by starting to invoice private insurance companies for Prostatype®. This marks a transition from an initial phase of clinical introduction and evaluation to a phase of established commercial use and the possibility of recurring revenue outside of the Medicare system.

Strengthened clinical evidence and scientific position

The clinical evidence for Prostatype® was strengthened by the publication of results from a Spanish multicentre study, where the test showed superior prognostic ability compared to established clinical risk models. The study confirms the clinical relevance of the test and its value as decision support when choosing between treatment options for patients with prostate cancer. The publication constitutes an important contribution to the overall scientific documentation and is expected to facilitate continued clinical adoption, both in Europe and in other markets.

Financing

The company's financial position was strengthened through the exercise of warrants of series TO5, which provided the company with approx. 11.5 MSEK in cash. The capital injection has improved the conditions for financing the continued commercial expansion, clinical support work and ongoing development efforts.

Strategic development and future product opportunities

During the second half of the year, the company also communicated a further developed strategy for research and development, with a focus on further use of the existing technology platform behind Prostatype®. The strategy aims to create conditions for future complementary products and potential new applications, which can contribute to broadened revenue opportunities and increased value creation over time.



Significant events after the end of the period

Publication of U.S. validation study

The clinical evidence was further strengthened with the publication of the company's U.S. validation study for Prostatype® in the medical journal Prostate Cancer and Prostatic Diseases. The study, conducted in collaboration with Veteran Affairs and Cedars-Sinai Health System, included a diverse patient population and demonstrated once again that the test demonstrates strong and significant prognostic ability to support clinical decisions in prostate cancer diagnostics. This publication further strengthens the evidence base in the United States and contributes to increased clinical credibility in the most important international market.

Loan financing

In December 2025 and January 2026, the company was provided with additional financial flexibility through the signing of short-term loans totalling 10 MSEK, including loans from both major shareholders and external lenders. The financing aims to secure short-term working capital without an immediate dilution effect for the shareholders.



CEO Fredrik Rickman comments

2025 was a challenging year in many ways, not least in the world around us. For Prostatype Genomics, the company has continued to develop in the right direction during the year with a clear focus on launching Prostatype® in the U.S., obtaining cost reimbursement for the product from Medicare, and strengthening our scientific basis through several new published studies, including from the U.S., which has further strengthened the scientific evidence for Prostatype®.

In the U.S., we have passed the introduction phase for Prostatype® in 2025 with good clinical results, which meant that we were able to start invoicing U.S. insurance companies, albeit on a small scale. We have however not yet reached the finish line of the Medicare process, and it has taken longer to reach this goal than we originally expected. An approval from Medicare is strategically important as most patients who suffer from prostate cancer in the United States are insured through this specific organization. For obvious reasons, I receive many questions from both shareholders and other initiated persons about when an approval can be expected. The dialogue with Medicare is proceeding in a positive way, but despite this it is difficult to say when an approval will come as regulatory processes are generally complex and time-consuming.

When looking at the broader picture, I cannot help but note that in the field of molecular diagnostics, several structural or strategic transactions have been carried out in recent years. These deals have typically included companies with clinically validated tests approved for the U.S. market. In industrial assessments, factors such as the quality of the

evidence, reimbursement possibilities, the robustness of the technology platform and the company's position in the healthcare treatment flows are usually taken into account. Since the prostate cancer field is a segment with continuous growth, and of strategic interest to many commercial players, interest in the segment is expected to remain high.

At the same time, the valuation of smaller listed growth companies may be affected by broader market conditions such as capital availability, risk appetite, liquidity and the general capital market climate. These factors vary over time and do not always fully reflect the long-term assessments that form the basis for strategic transactions and the commercial value that a technology platform in the segment can represent.

An important component to further build commercial value in the company is the work to broaden the area of use of Prostatype® to also include patients who have already undergone a radical treatment for their prostate cancer. A first study has already been conducted with good results, and publication in a scientific journal is expected in 2026.

// In the U.S., we have passed the introduction phase for Prostatype® in 2025 with good clinical results, which meant that we were able to start invoicing U.S. insurance companies, albeit on a small scale.


My assessment is that this further development of Prostatype® will have positive commercial effects in the U.S., as well as in the European and Asian markets.

During the year, the company conducted financing activities that supported the business in the ongoing commercialization phase and the further development of our technology platform. That said, the need for additional capital for commercial expansion remains.

Looking ahead, I see excellent opportunities. Our market continues to grow globally, and we have a product with excellent performance. Our direction is clear: we will grow in sales, strengthen our innovation power and continue to focus on building value for our shareholders. With the expertise, commitment and team spirit that exists in the organization, we are well equipped for the future.

I would like to conclude by extending a big thank you to the company's employees, partners and of course to all our shareholders for your trust and commitment. I am convinced that in 2026, we will see Prostatype Genomics take further significant steps forward both commercially and organizationally.

Fredrik Rickman
CEO Prostatype Genomics AB
Nacka Strand, 26 February 2026



Key figures

Group

TSEK	2025 July-Dec	2024 July-Dec	2025 Full year	2024 Full year
Net sales	348	84	594	199
EBITDA	-17,780	-20,437	-36,751	-38,874
Total Assets	50,862	41,970	50,862	41,970
Total Equity	26,529	33,469	26,529	33,469
Net cash flow	-3,846	7,620	-330	6,686
Equity/Assets-ratio	52%	80%	52%	80%
Number of employees EoP	6	6	6	6
Equity per share, SEK *	0.45	4.99	0.45	4.99
Earnings per share, SEK * **				
- Before dilution	-0.40	-5.00	-1.32	-14.93
- After dilution	-0.40	-5.00	-1.32	-14.93
Number of shares at the end of the period	59,189,321	6,704,770	59,189,321	6,704,770
Number of shares at the end of the period after full dilution	59,189,321	6,704,770	59,189,321	6,704,770
Average number of shares for the period	51,792,969	2,048,622,457	33,783,778	1,410,722,766

* Values for historic earnings and equity per share have been recalculated to reflect the reversed share split 1000:1 decided upon at the extraordinary general meeting on 22 October 2024.

** The definition of earnings per share has been updated to be calculated on the average number of shares for the period instead of on the number of shares at the end of the period. All comparative figures have therefore been adjusted.

Definition of key ratios

Equity/debt ratio

Equity / total assets

Equity per share

Equity / number of shares by period closing

Earnings per share

Net profit/loss for the year / average number of shares for the period

Diluted earnings per share

Net profit/loss for the year / (average number of shares + warrants for the period)

Financial development

Second half of 2025

Net sales and results

Net sales for the second half of 2025 amounted to 348 TSEK (84), of which 112 TSEK (0) is related to the United States. The group is still in the initial phase of commercialization, and thus the net sales is in line with expectations.

Operation profit/loss for the company (EBIT) and operating profit before depreciation and amortization (EBITDA) amounted to -18,872 TSEK (-21,453) and -17,780 TSEK (-20,437), respectively. The company's costs mainly consist of research, testing, personnel and commercialization, with the main focus on preparations ahead of a U.S. launch.

Earnings per share for the period amounted to -0.40 SEK (-5.00) where recalculation was made to reflect the 1000:1 reverse share split that was carried out during the second half of 2024.

Investments

The investments mainly relate to product development in and towards the United States and amount to a total of 12,030 TSEK (1 822).

Cash flow and liquid assets

Net cash flow during the period amounted to 3,846 TSEK (7,620). The group's cash and cash equivalents at the end of the period amounted to 9,068 TSEK (9,420).

The company's financial position was strengthened during the second half of the year through the exercise of warrants of series TO5, which provided the company with approximately 11.5 MSEK in cash before issue-related costs.

The parent company

The parent company's income and operating result for the period amounted to 236 TSEK (84) and -12,109 TSEK (-14,881), respectively. The company invested 11,986 TSEK (666) in product development and financed subsidiaries with 5,460 TSEK (5,506). Net cash flow amounted to -3,998 TSEK (7,721) and cash and cash equivalents at the end of the period amounted to 8,467 TSEK (9,302).

Full year 2025

Net sales and result

Net sales amounted to 594 TSEK (199), of which 112 TSEK (0) is related to the United States. The company is still in the initial phase of commercialization, and thus the net sales is in line with expectations.

Operation profit/loss for the company (EBIT) and operating profit before depreciation and amortization (EBITDA) amounted to -38,938 TSEK (-40,853) and -36,751 TSEK (-38,874), respectively. The company's costs mainly consist of research, testing, personnel and commercialization.

Earnings per share for the period amounted to -1.32 SEK (-14.93), where recalculation was made to reflect the 1000:1 reverse share split that was carried out during the second half of 2024.

Investments

Investments relate primarily to product development in and towards the United States and amount to a total of 13,359 TSEK (8,356).

Cash flow and liquid assets

Net cash flow during the period amounted to -330 TSEK (-6,686). The Group's cash and cash equivalents at the end of the period amounted to 9,068 TSEK (9,420).

During the year, the company has received capital via a rights issue and warrants of series TO5 totalling 41.7 MSEK before issue costs.

The parent company

The parent company's income and operating result for the period amounted to 482 TSEK (199) and -25,319 TSEK (-30,293), respectively. The company invested 13,182 TSEK (3,816) in product development and financed subsidiaries with 9,507 TSEK (11,455). Net cash flow amounted to -835 TSEK (7,233) and cash and cash equivalents at the end of the period amounted to 8,467 TSEK (9,302).

The share

The company's share is listed on the NASDAQ First North Growth Market under the symbol PROGEN, and it is traded with ISIN code SE0023261532.

On 31 December 2025, the share capital amounted to 5,918,932 SEK (670,477) distributed over 59,189,321 shares (6,704,770). The increase is due to the rights issue of units that included warrants of series TO5, which were issued and subscribed for in 2025. All shares are issued and fully paid.

Since March 13, 2025, the company's share is also available for trading on the OTCQB Venture Market in the U.S., which means that the share there can be traded in parallel with its listing on Nasdaq First North in Stockholm, during U.S. trading hours, with a U.S. ticker (OTCQB: PGABF) and pricing in USD.

A list of the largest shareholders can be found on the company's website (www.prostatypegenomics.com).

The balance sheet

At the end of the period, the group had intangible fixed assets of 39,285 TSEK (29,267) and cash and cash equivalents of 9,068 TSEK (9,420). The group's intangible assets mainly represent values for expenses, development work and patents regarding the company's product. Development expenses and patents are written off on a straight-line basis over 10 years.

The group's equity amounted to 26,529 TSEK (33,469) and outstanding loans to 5,300 TSEK (67). The loans at the end of the period are short-term. At year-end, the group also had accounts payable of 10,567 TSEK (0) on payment plan.

Liquidity, financing, capital requirements

The board of directors makes the assessment that the group is dependent on additional capital injections until a positive operating cash flow is reached.

Based on ongoing financing activities, it is the board's assessment that the group will secure the liquidity required for the needs of the business. The board of directors works proactively to secure growth capital through a combination of debt financing, new issues and strategic collaborations to accelerate commercialization. It is the Board's overall conclusion that these measures will ensure continued operations, which is why the report is prepared with the going concern assumption.

However, the board of directors would like to draw attention to the fact that if the necessary additional financing is not realised, this will constitute a material uncertainty factor for the group's ability to continue operations over the next 12 months.

Forward-looking statements

Certain statements in this report are forward-looking and actual results may differ materially. In addition to the factors discussed, other factors may have an impact on actual outcomes. Such factors include developments for customers, competitors, effects of economic and market conditions, national and international laws and regulations, tax regulations, fluctuations in exchange rates and interest rates and political risks.



Profit & loss

Consolidated income statement

TSEK	2025 Jul-Dec	2024 Jul-Dec	2025 Jan-Dec	2024 Jan-Dec
Net sales	348	84	594	199
Own work capitalized	-	386	-	1,719
Other operating income	3	-0	3	65
Total income	351	469	597	1,983
Research and development cost	-1,045	-1,231	-1,464	-2,211
Other external costs	-9,486	-11,539	-20,798	-22,355
Staff cost	-7,787	-7,812	-15,225	-15,709
Depreciation and impairment of tangible and intangible fixed assets	-1,092	-1,016	-2,187	-1,979
Other operating expenses	187	-324	139	-583
Total operating costs	-19,224	-21,922	-39,535	-42,836
Operating profit/loss (EBIT)	-18,872	-21,453	-38,938	-40,853
Interest income and similar items	90	42	90	43
Interest expense and similar items	-1,388	-850	-1,615	-1,677
Currency effects	-413	875	-4,041	1,436
Profit/loss after financial items	-20,583	-21,386	-44,503	-41,051
Current tax	-	-	-	-
Net profit/loss for the period	-20,583	-21,386	-44,503	-41,051

Balance

Consolidated balance sheet in summary

TSEK	2025-12-31	2024-12-31
ASSETS		
Non-current intangible assets	39,285	29,267
Non-current tangible assets	452	312
Non-current financial assets	485	566
Total non-current assets	40,221	30,145
Inventory	78	95
Other current receivables	1,495	1,785
Subscribed but not paid-up rights issue	-	525
Cash and bank	9,068	9,420
Total current assets	10,641	11,825
Total assets	50,862	41,970
Equity and liabilities		
Share capital	5,919	670
Other capital	211,817	183,687
Other equity including net profit/loss for the period	-191,206	-150,888
Total equity	26,529	33,469
Non-current liabilities	-	-
Current liabilities	24,333	8,501
Total liabilities	24,333	8,501
Total equity and liabilities	50,862	41,970
Pledged securities	-	3,614
Contingent liabilities	-	-

Cash

Consolidated cash flow statement

TSEK	2025 Jul-Dec	2024 Jul-Dec	2025 Jan-Dec	2024 Jan-Dec
Profit/loss after financial items	-20,583	-21,386	-44,503	-41,051
Adjustments for items not included in cash flow etc.	2,770	516	7,719	916
Cash flow from operating activities before changes in working capital	-17,813	-20,869	-36,785	-40,135
Change in inventory	86	106	16	109
Change in operating receivables	-226	-584	264	-244
Change in operating liabilities	11,231	-152	12,703	-4,439
Changes in working capital	11,091	-629	12,983	-4,574
Cash flow from operating activities	-6,722	-21,499	-23,801	-44,709
Investments in intangible assets	-11,986	-1,052	-13,182	-7,578
Investments in tangible assets	-30	-285	-258	-285
Change in financial assets	-14	-485	81	-493
Cash flow from investment activities	-12,030	-1,822	-13,359	-8,356
Share issue proceeds, net	9,606	36,766	31,597	66,151
Loans raised	5,300	-	10,550	8,825
Loans amortized	-	-5,825	-5,317	-15,225
Cash flow from financing activities	14,906	30,941	36,831	59,751
Cash flow for the period	-3,846	7,620	-330	6,686
Cash and cash equivalents at the beginning of the period	12,932	1,785	9,420	2,682
Exchange differences cash and cash equivalents	-18	15	-23	52
Cash and cash equivalents at the end of the period	9,068	9,420	9,068	9,420

Equity

Consolidated changes in equity

TSEK	Share capital	Other capital/ premium reserves	Other equity including net profit/ loss for the year	Total equity
Opening balance 2024-01-01	7,168	177,153	-159,647	24,674
Reduction of share capital	-56,942	5,973	50,969	-
New share issues	50,445	11,033	-	61,478
New share issues, subscribed not paid-up	-	13	-	13
Issue expenses	-	-10,486	-	-10,486
Exchange differences	-	-	-1,158	-1,158
Profit/loss for the period	-	-	-41,051	-41,051
Closing balance 2024-12-31	670	183,687	-150,888	33,469
Opening balance 2025-01-01	670	183,687	-150,888	33,469
New share issues	5,248	36,455	-	41,703
Issue expenses	-	-8,325	-	-8,325
Exchange differences	-	-	4,185	4,185
Profit/loss for the period	-	-	-44,503	-44,503
Closing balance 2025-12-31	5,919	211,817	-191,206	26,529

The share capital of 5,918,932 SEK (670,477) is distributed over 59,189,321 shares (6,704,770).

Parent company

Parent company condensed financial statements

Income statement

TSEK	2025 Jul-Dec	2024 Jul-Dec	2025 Full year	2024 Full year
Income	239	149	485	264
Operating expenses	-11,304	-14,067	-23,715	-28,395
Depreciation, amortization and impairment	-1,045	-963	-2,089	-1,899
Operating profit/loss	-12,109	-14,881	-25,319	-30,029
Financial items	-2,516	-11,304	-9,327	-11,021
Profit/loss after financial items	-14,625	-26,185	-34,647	-41,051
Taxes	-	-	-	-
Net profit/loss for the period	-14,625	-26,185	-34,647	-41,051

Balance sheet

TSEK	2025-12-31	2024-12-31
Non-current assets	43,633	33,024
Current assets excl. cash and cash equivalents	7,323	6,800
Cash and cash equivalents	8,467	9,302
Total Assets	59,423	49,126
Equity	39,883	41,150
Non-current liabilities	-	-
Current liabilities	19,540	7,975
Total equity and liabilities	59,423	49,126

Cash flow statement

TSEK	2025 Jul-Dec	2024 Jul-Dec	2025 Full year	2024 Full year
Cash flow from operating activities	-1,414	-16,278	-14,801	-36,470
Cash flow from investing activities	-17,490	-6,942	-22,866	-16,048
Cash flow from financing activities	14,906	30,941	36,831	59,751
Cash flow for the period	-3,998	7,721	-835	7,233
Cash balance at the end of the period	8,467	9,302	8,467	9,302

Changes in equity

TSEK	Share capital	Other restricted capital	Development fund	Share Premium	Profit/loss brought forward	Total
Opening balance 2024-01-01	7,168	275	14,853	176,878	-167,978	31,196
New share issues	-56,942	5,973	-	-	50,969	-
Reduction of share capital	50,445	-6,248	-	17,281	-	61,478
Net share issues, subscribed not paid-up	-	13	-	-	-	13
Issue expenses	-	-	-	-10,486	-	-10,486
Change in development fund	-	-	-1,857	-	1,857	-
Profit/loss for the period	-	-	-	-	-41,051	-41,051
Closing balance 2024-12-31	670	13	12,996	183,674	-156,203	41,150
New share issues	5,248	-13	-	36,468	-	41,703
Issue expenses	-	-	-	-8,325	-	-8,325
Change in development fund	-	-	-1,857	-	1,857	-
Profit/loss for the period	-	-	-	-	-34,647	-34,647
Closing balance 2025-12-31	5,919	-	11,140	211,817	-188,993	39,883

General information

Company information

Prostatype Genomics AB with organization number 556726-0285 is a limited company registered in Sweden, domiciled in Stockholm. The address is Augustendalsvägen 20, SE-131 52 Nacka Strand.

The company is engaged in the research and developments of medical devices and the sales of these.

Prostatype® is the result of more than fifteen years of research into the genomics of prostate cancer. The company was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market ready product Prostatype® Test System. Prostatype® is a test for diagnosis and prognosis that has been developed to provide the complementary information that is often needed for the selection of the optimal treatment strategy for each patient. The test analyzes the gene expression in cancer cells from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed. Aided by AI (Artificial Intelligence) technology, the gene test of Prostatype Genomics makes it possible to make a better prognosis and to classify the patient's illness into different risk types. In that way the company can reduce the risk of over- or under treatment, which in many cases lead to great discomfort for the patient. Prostatype® is today the only genetic test for prostate cancer that is available in kit format. The product is also very scalable in terms of volume due to the algorithm that forms the basis of the test.

All figures in the report are in thousands of Swedish kronor (TSEK) if not otherwise specified. Amounts or information in parentheses refer to the corresponding period of the previous year. Rounding differences may therefore occur.

Accounting principles

The report has been prepared in accordance with BFNAR 2012:1 Årsredovisning och koncernredovisning (K3) issued by the Swedish Accounting Standards Boards (BFN). The accounting policy for the company complies with applied accounting principles for the most recent published annual report.

Transactions with related parties

Shareholder loans

In December 2025 and January 2026, the company signed short-term loan agreements with board members and major shareholders, of which 2.0 MSEK with board members, Håkan Englund with 1.5 MSEK, Anders Lundberg with 0.2 MSEK, Michael Häggman with 0.2 MSEK and Jörgen Dahlström with 0.1 MSEK. The loans have a fixed period interest rate of 15% and run until June 30, 2026. The loans were signed privately or through controlled companies.

Consultancy fees

Board member Mattias Prage is employed at Advokatbyrå Lindahl KB, which the company engages for advice on legal issues and company administration. During the year, Lindahl invoiced the company 645 TSEK (1 036).

Board member Jörgen Dahlström is CEO of Mercodia AB, which has purchased consulting services from the company for 145 TSEK (0).

Johan Waldhe, who was a board member up until the 2025 annual general meeting, is CEO of the communications and consulting company Honeybadger AB. Services for 616 TSEK (711) were procured during the time of the board assignment.

Material risks and uncertainties in summary

A description of the most significant market and business related risks can be found in the annual report for 2023, as well as in the prospectus submitted and published on the company's website www.prostatypegenomics.com

Valuation of assets

The company's product, Prostatype®, is in a commercialization phase. In addition the short-term financial risk above, there is, as with all businesses, a long-term risk that objectives will not be achieved within the time frame on which the group's forecasts are based. If the sales do not reach the set goals so that the assumed cash flows do not occur at the rate assumed by the board and company management or are alternatively postponed further in time, or if other assumptions that formed the basis of the impairment test carried out by the company management would change in a negative way, this may lead to the intangible assets being written down at a faster rate than planned.

Other information

Financial calendar

Annual report 2025:	2026-04-17
Annual general meeting 2026:	2026-05-08
Interim report H1 2026:	2026-07-23
Year-end report 2026:	2027-02-11

The company's financial reports are available on prostatypegenomics.com

Review

This interim report has not been subject to review by the company's auditors.

Certified Advisor

Tapper Partners AB
Telephone: +46 (0)70-44 010 98
Email: ca@tapperpartners.se

Publication

This information is such information that Prostatype Genomics AB is obliged to make public according to the EU's market abuse regulation. The information was submitted, through the contact person below, for publication on 26 February, 2026.

Fredrik Rickman, CEO
fredrik.rickman@prostatypegenomics.com

Signing of the report

The board and the CEO assure that the year-end report provides a fair overview of the group's and the parent company's operations, balance and results, and describes the significant risks and uncertainty factors that the group is facing.

Nacka Strand, 26 February, 2026

Anders Lundberg
Chairman

Håkan Englund
Board member

Michael Häggman
Board member

Mattias Prage
Board member

Jörgen Dahlström
Board member

Fredrik Rickman
CEO

Phone: +46 (0)8-20 87 00
Website: www.prostatypegenomics.com



Prostatype Genomics AB

Augustendalsvägen 20, SE-131 52 Nacka Strand

Phone: +46 (0)8-20 87 00

Website: www.prostatypegenomics.com